Market capitalization | $9.05b |
Enterprise Value | $13.25b |
P/E (TTM) P/E ratio | 23.89 |
EV/FCF (TTM) EV/FCF | 18.92 |
EV/Sales (TTM) EV/Sales | 1.05 |
P/S ratio (TTM) P/S ratio | 0.71 |
P/B ratio (TTM) P/B ratio | 2.67 |
Revenue growth (TTM) Revenue growth | 2.71% |
Revenue (TTM) Revenue | $12.67b |
As a Free StocksGuide user, you can view scores for all 6,814 stocks worldwide.
16 Analysts have issued a Henry Schein forecast:
16 Analysts have issued a Henry Schein forecast:
Dec '24 |
+/-
%
|
||
Revenue | 12,673 12,673 |
3%
3%
|
|
Gross Profit | 3,765 3,765 |
3%
3%
|
|
EBITDA | 1,028 1,028 |
9%
9%
|
EBIT (Operating Income) EBIT | 731 731 |
5%
5%
|
Net Profit | 390 390 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.
Head office | United States |
CEO | Stanley Bergman |
Employees | 25,000 |
Founded | 1932 |
Website | www.henryschein.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.